DWA
KPTI icon

Dorsey Wright & Associates’s Karyopharm Therapeutics KPTI Stock Holding History

Dorsey Wright & Associates’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-61
Closed -$18K – 336
2020
Q1 		$18K Sell
61
-2
-3% -$552 0.01% 110
2019
Q4 		$18K Buy
+63
New +$13.7K 0.01% 133

Other funds holding KPTI

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Dorsey Wright & Associates's KPTI Position: Q2 2020 in Review

Dorsey Wright & Associates sold out of Karyopharm Therapeutics (KPTI) in Q2 2020, closing a stake of 61 shares — an estimated $18K sold.

Dorsey Wright & Associates first reported a position in KPTI in Q4 2019 and held it in 2 quarters. The position peaked at $18K in Q1 2020. 155 funds tracked by Wall St. Rank hold KPTI as of Q2 2020.

  • Dorsey Wright & Associates reported no remaining Karyopharm Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Dorsey Wright & Associates sold 61 Karyopharm Therapeutics shares in Q2 2020, an estimated $18K.
  • Dorsey Wright & Associates first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 2 quarters.
  • Dorsey Wright & Associates's Karyopharm Therapeutics position peaked at $18K in Q1 2020.
  • 155 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2020.

Based on Dorsey Wright & Associates's 13F filing for Q2 2020, filed 23 Jul 2020.